These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26231955)

  • 1. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration.
    Chen N; Brachmann C; Liu X; Pierce DW; Dey J; Kerwin WS; Li Y; Zhou S; Hou S; Carleton M; Klinghoffer RA; Palmisano M; Chopra R
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):699-712. PubMed ID: 26231955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin-bound paclitaxel: a next-generation taxane.
    Gradishar WJ
    Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
    Desai N; Trieu V; Yao Z; Louie L; Ci S; Yang A; Tao C; De T; Beals B; Dykes D; Noker P; Yao R; Labao E; Hawkins M; Soon-Shiong P
    Clin Cancer Res; 2006 Feb; 12(4):1317-24. PubMed ID: 16489089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma.
    Zhou Q; Ching AK; Leung WK; Szeto CY; Ho SM; Chan PK; Yuan YF; Lai PB; Yeo W; Wong N
    Int J Oncol; 2011 Mar; 38(3):721-31. PubMed ID: 21240457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations.
    Zhang DY; Dmello C; Chen L; Arrieta VA; Gonzalez-Buendia E; Kane JR; Magnusson LP; Baran A; James CD; Horbinski C; Carpentier A; Desseaux C; Canney M; Muzzio M; Stupp R; Sonabend AM
    Clin Cancer Res; 2020 Jan; 26(2):477-486. PubMed ID: 31831565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
    Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T
    Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing Nab-Paclitaxel Delivery Using Microbubble-Assisted Ultrasound in a Pancreatic Cancer Model.
    Bressand D; Novell A; Girault A; Raoul W; Fromont-Hankard G; Escoffre JM; Lecomte T; Bouakaz A
    Mol Pharm; 2019 Sep; 16(9):3814-3822. PubMed ID: 31356090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
    Neesse A; Frese KK; Chan DS; Bapiro TE; Howat WJ; Richards FM; Ellenrieder V; Jodrell DI; Tuveson DA
    Gut; 2014 Jun; 63(6):974-83. PubMed ID: 24067278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.
    Kim H; Samuel S; Lopez-Casas P; Grizzle W; Hidalgo M; Kovar J; Oelschlager D; Zinn K; Warram J; Buchsbaum D
    Mol Cancer Ther; 2016 Apr; 15(4):680-8. PubMed ID: 26832793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
    Petrelli F; Borgonovo K; Barni S
    Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles.
    Li F; Zhang H; He M; Liao J; Chen N; Li Y; Zhou S; Palmisano M; Yu A; Pai MP; Yuan H; Sun D
    Mol Pharm; 2018 Oct; 15(10):4505-4516. PubMed ID: 30180593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy.
    Yang J; Lv Q; Wei W; Yang Z; Dong J; Zhang R; Kan Q; He Z; Xu Y
    Drug Deliv; 2018 Nov; 25(1):807-814. PubMed ID: 29553858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. nab-Paclitaxel mechanisms of action and delivery.
    Yardley DA
    J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
    Sparreboom A; Verweij J; van der Burg ME; Loos WJ; Brouwer E; Viganò L; Locatelli A; de Vos AI; Nooter K; Stoter G; Gianni L
    Clin Cancer Res; 1998 Aug; 4(8):1937-42. PubMed ID: 9717822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
    Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
    J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors.
    Zhang L; Marrano P; Kumar S; Leadley M; Elias E; Thorner P; Baruchel S
    Clin Cancer Res; 2013 Nov; 19(21):5972-83. PubMed ID: 23989978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
    Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate.
    Gao M; Zhang D; Yao N; Jin Q; Jiang C; Zhang J; Wang F
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1187-1194. PubMed ID: 31520101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor.
    Sheihet L; Garbuzenko OB; Bushman J; Gounder MK; Minko T; Kohn J
    Eur J Pharm Sci; 2012 Feb; 45(3):320-9. PubMed ID: 22155544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.